833a – Efficacy in Biologic-Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderatesevere Ulcerative Colitis: Unifi
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Rupert W. Leong(The University of Sydney), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), Stephan R. Targan(Cedars-Sinai Medical Center), David Rowbotham(University of Auckland), Colleen Marano(Johnson & Johnson (United States)), Christopher D. O’Brien(Cedars-Sinai Medical Center), Philippe Szapary(Cedars-Sinai Medical Center), Jewel Johanns(Johnson & Johnson (United States)), Gert A. Van Assche, Hongyan Zhang(Northwest A&F University), Ramesh Arasaradnam(University Hospital Coventry)
Cited by 3
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k